News Releases

Jun 01, 2021
SHANGHAI and GAITHERSBURG, Md. , June 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been
May 27, 2021
SHANGHAI and GAITHERSBURG, Md. , May 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in June.
May 13, 2021
SH ANGHAI and GAITHERSBURG, Md. , May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab has been selected for inclusion in the MSCI
Apr 29, 2021
SHANGHAI and GAITHERSBURG, Md. , April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in May.
Apr 28, 2021
SHANGHAI and GAITHERSBURG, Md. , April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form
Displaying 21 - 30 of 49